Compare MREO & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MREO | UPXI |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 77.0M |
| IPO Year | 2017 | 2021 |
| Metric | MREO | UPXI |
|---|---|---|
| Price | $0.33 | $1.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.50 | ★ $2.00 |
| AVG Volume (30 Days) | 1.4M | ★ 4.3M |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 92.49 |
| EPS | N/A | ★ 0.76 |
| Revenue | $500,000.00 | ★ $15,811,345.00 |
| Revenue This Year | $6,000.20 | $118.99 |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | $1.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.54 |
| 52 Week High | $2.94 | $22.53 |
| Indicator | MREO | UPXI |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 58.78 |
| Support Level | $0.32 | $0.91 |
| Resistance Level | $0.42 | $1.28 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 29.29 | 84.26 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.